Axa grew its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 12.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,900 shares of the biotechnology company’s stock after buying an additional 3,100 shares during the quarter. Axa’s holdings in Heron Therapeutics were worth $883,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of HRTX. BlackRock Inc. lifted its holdings in shares of Heron Therapeutics by 29.4% in the 2nd quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock worth $176,563,000 after buying an additional 1,032,010 shares during the period. FMR LLC lifted its holdings in shares of Heron Therapeutics by 6.5% in the 2nd quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after buying an additional 693,699 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth $15,249,000. First Light Asset Management LLC lifted its holdings in shares of Heron Therapeutics by 76.8% in the 2nd quarter. First Light Asset Management LLC now owns 836,737 shares of the biotechnology company’s stock worth $32,507,000 after buying an additional 363,462 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Heron Therapeutics by 396.2% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 342,400 shares of the biotechnology company’s stock worth $10,837,000 after buying an additional 273,400 shares during the period.
In related news, VP Kimberly Manhard sold 6,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $32.07, for a total transaction of $192,420.00. Following the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at approximately $192,420. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kevin C. Tang sold 2,695,000 shares of the company’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,701,494 shares of company stock valued at $96,553,796 over the last 90 days. 16.20% of the stock is currently owned by company insiders.
Shares of NASDAQ HRTX opened at $27.88 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of 7.64 and a beta of 1.48. Heron Therapeutics Inc has a 1-year low of $15.00 and a 1-year high of $42.90.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). The company had revenue of $19.79 million for the quarter, compared to analysts’ expectations of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company’s revenue for the quarter was up 130.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.77) earnings per share. As a group, analysts anticipate that Heron Therapeutics Inc will post -2.34 earnings per share for the current fiscal year.
Heron Therapeutics Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: Is a Roth IRA right for you?
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.